Adjuvant treatment of pancreatic carcinoma in a clinically adapted mouse resection model

Pancreatology

Volumn 6, Issue 3, 2006, Pages 240-247

  Tepel, Juergen ^a   Kruse, Marie Luise ^a   Kapischke, Matthias ^a   Haye, Sieglinde ^a   Sipos, Bence ^a   Kremer, Bernd ^a   Kalthoff, Holger ^a  

^a UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

Author keywords

Adjuvant treatment; Pancreas resection model

Indexed keywords

CYTOTOXIC AGENT; GEMCITABINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER ADJUVANT THERAPY; CANCER CELL; CANCER CHEMOTHERAPY; CANCER INHIBITION; CANCER RECURRENCE; CANCER SURGERY; CONTROLLED STUDY; DISEASE COURSE; DRUG EFFICACY; FEASIBILITY STUDY; FEMALE; HUMAN; HUMAN CELL; INOCULATION; METASTASIS; MOUSE; NONHUMAN; PANCREAS CARCINOMA; PANCREAS RESECTION; PRIORITY JOURNAL; SOLID TUMOR; STATISTICAL SIGNIFICANCE; TUMOR GROWTH; TUMOR VOLUME; XENOTRANSPLANTATION;

EID: 33746352042     PISSN: 14243903     EISSN: 14243911     Source Type: Journal    
DOI: 10.1159/000092027     Document Type: Article

References (39)

1. Lillemoe KD: Current management of pancreatic carcinoma. Ann Surg 1995;221:133-148.
2. Ishikawa O: Surgical technique, curability and postoperative quality of life in an extended pancreatectomy for adenocarcinoma of the pancreas. Hepatogastroenterology 1996;43:320-325.
3. Sperti C, Pasquali C, Piccoli A, Pedrazzoli S: Survival after resection for ductal adenocarcinoma of the pancreas. Br J Surg 1996;83:625-631.
4. Wanebo HJ, Vezeridis MP: Pancreatic carcinoma in perspective. A continuing challenge. Cancer 1996;78(suppl):580-591.
5. Henne-Bruns D, Vogel I, Luettges J, Kloeppel G, Kremer B: Ductal adenocarcinoma of the pancreas head: survival after regional versus extended lymphadenectomy. Hepatogastroenterology 1998;45:855-866.
6. Magistrelli P, Antinore A, Crucitti A, La Greca A, Masetti R, Coppola R, Nuzzo G, Picciochi A: Prognostic factors after surgical resection for pancreatic carcinoma. J Surg Oncol 2001;74:36-40.
7. Lim JE, Chien MW, Earle CC: Prognostic factors following curative resection for pancreatic adenocarcinoma. Ann Surg 2003;237:74-85.
8. Trede M, Wendl K, Richter A: Pancreatic carcinoma - conclusions and prospects. Langenbecks Arch Surg 1998(suppl 115):411-420.
9. Sperti C, Pasquali C, Piccoli A, Pedrazzoli S: Recurrence after resection for ductal adenocarcinoma of the pancreas. World J Surg 1997;21:195-200.
10. Regine WF, John WJ, Mohiuddin M: Adjuvant therapy for pancreatic cancer: current status. Front Biosci 1998;3:186-192.
11. Berlin JD, Rothenberg M: Chemotherapy for respectable and adjuvant pancreatic cancer. Oncology 2001;15:1241-1254.
12. Breslin TM, Hess KR, Harbison DB, Jean ME, Cleary KR, Dackiw AP, Wolff RA, Abbruzzese JL, Janjan NA, Crane CH, Vauthey JN, Lee JE, Pisters PW, Evans DB: Neoadjuvant chemoradiotherapy for adenocarcinoma of the pancreas: treatment variables and survival duration. Ann Surg Oncol 2001;8:123-132.
13. Neoptolemos JP, Stocken D, Friess H, Bassi C, Dunn JA, Hickey H, Beger H, Fernando-Cruz L, Dervenis C, Lacaine F, Falconi M, Pederzoli P, Pap A, Spooner D, Kerr DJ, Büchler MW: A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. N Engl J Med 2004;350:1200-1210.
14. Aristu J, Canon R, Pardo F, Martinez-Monge R, Martin-Algarra S, Ordonez M, Villafranca E, Moreno M, Cambeiro M, Azinovic I: Surgical resection after preoperative chemoradiotherapy benefits selected patients with unresectable pancreatic cancer. Am J Clin Oncol 2003;26:30-36.
15. Brunner TB, Grabenbauer GG, Klein P, Baum U, Papadopoulos T, Bautz W, Hohenberger W, Sauer R: Phase I trial of strictly time-scheduled gemcitabine and cisplatin with concurrent radiotherapy in patients with locally advanced pancreatic cancer. Int J Radiat Oncol Biol Phys 2003;55:144-153.
16. Heinemann V: Gemcitabine: progress in the treatment of pancreatic cancer. Oncology 2001;60:8-18.
17. Oettle H, Arnold D, Hempel C, Riess H: The role of gemcitabine alone and in combination in the treatment of pancreatic cancer. Anticancer Drugs 2000;11:771-786.
18. Prost P, Ychou M, Azria D: Gemcitabine and pancreatic cancer. Bull Cancer 2002;89:91-95.
19. Jacobs AD: Gemcitabine-based therapy in pancreas cancer: gemcitabine-docetaxel and other novel combinations. Cancer 2002;95(suppl):923- 927.
20. Corrie P, Mayer A, Shaw J, D'Ath S, Bladgen S, Blesing C, Price P, Warner N: Phase II study to evaluate combining gemcitabine with flutamide in advanced pancreatic cancer patients. Br J Cancer 2002;87:716-719.
21. Neri B, Cini G, Doni L, Fulignati C, Turrini M, Pantalone D, Mini E, De Luca Cardillo C, Fioretto LM, Ribecco AS, Moretti R, Statizzi M, Zocchi G, Quattrone A: Weekly gemcitabine plus epirubicin as effective chemotherapy for advanced pancreatic cancer: a multicenter phase II study. Br J Cancer 2002;87:497-501.
22. Louvet C, Andre T, Lledo G, Hammel P, Bleiberg H, Bouleuc C, Gamelin E, Flesch M, Cvitkovic E, de Gramont A: Gemcitabine combined with oxaliplatin in advanced pancreatic adenocarcinoma: final results of a GERCOR multicenter phase II study. J Clin Oncol 2002;20:1512-1518.
23. McGinn CJ, Lawrence TS, Zalupski MM: On the development of gemcitabine-based chemoradiotherapy regimens in pancreatic cancer. Cancer 2002;95(suppl):933-940.
24. Kim HJ, Czischke K, Brennan MF, Conlon KC: Does neoadjuvant chemoradiation down-stage locally advanced pancreatic cancer? J Gastrointest Surg 2002;6:736-739.
25. Epelbaum R, Rosenblatt E, Nasrallah S, Faraggi D, Gaitini D, Mizrahi S, Kuten A: Phase II study of gemcitabine combined with radiation therapy in patients with localized, unresectable pancreatic cancer. J Surg Oncol 2002;81:138-143.
26. Kalthoff H, Schmiegel W, Roeder C, Kasche D, Schmidt A, Lauer G, Thiele HG, Honold G, Pantel K, Riethmueller G, Scherer E, Mauerer J, Maacke H, Deppert W: p53 and K-RAS alterations in pancreatic epithelial cell lesions. Oncogene 1993;8:289-298.
27. Tepel J, Kruse ML, March C, Fiedler A, Kapischke M, Ketterer T, Sipos B, Kremer B, Kalthoff H: Terminally modified oligodeoxynucleotides directed against p53 in an orthotopic xenograft model: a novel adjuvant treatment strategy for pancreatic ductal carcinoma. Pancreas 2004;28:1-12.
28. Buckwell A: Limiting clinical signs appendices. Lab Anim Sci Assoc Winter Newsl, 1992;16-17.
29. Bruns C, Solorzano CC, Harbison MT, Ozawa S, Tsan R, Fan D, Abbruzzese J, Traxler P, Buchdunger E, Radinsky R, Fidler IJ: Blockade of the epidermal growth factor receptor signalling by a novel tyrosine kinase inhibitor leads to apoptosis of endothelial cells and therapy of human pancreatic carcinoma. Cancer Res 2000;60:2926-2935.
30. Pour P, Mohr U, Cardesa A, Althoff J, Kruger FW: Pancreatic neoplasms in an animal model: morphological, biological, and comparative studies. Cancer 1975;36:379-389.
31. Fu X, Guadagni F, Hoffman RM: A metastatic nude-mouse model of human pancreatic cancer constructed orthotopically with histologically intact patient specimens. Proc Natl Acad Sci USA 1992;89:5645-5649.
32. Cui JH, Kruger U, Vogel I, Luettges J, Henne-Bruns D, Kremer B, Kalthoff H: Intact tissue of gastrointestinal cancer specimen orthotopically transplanted into nude mice. Hepatogastroenterology 1998;45:2087-2096.
33. Mohammad RM, Dugan MC, Mohamed AN, Almatchy VP, Flake TM, Dergham ST, Shields AF, Al-Katib AA, Vaitkevicius VK, Sarkar FH: Establishment of a human pancreatic tumour xenograft model: potential application for preclinical evaluation of novel therapeutic agents. Pancreas 1998;16:19-25.
34. Alves F, Contag S, Missbach M, Kaspareit .T, Nebendahl K, Borchers U, Heidrich B, Streich R, Hiddemann W: An orthotopic model of ductal adenocarcinoma of the pancreas in severe combined immunodeficient mice representing all steps of the metastatic cascade. Pancreas 2001;23:227-235.
35. Wang B, Shi Q, Abbruzzese JL, Xiong Q, Le X, Xie K: A novel clinically relevant animal model of metastatic pancreatic adenocarcinoma biology and therapy. Int J Pancreatol 2001;29:37-46.
36. Schreiner B, Greten FR, Baur DM, Fingerle AA, Zechner LJ, Bohm C, Schmid M, Hameister H, Schmid RM: Murine pancreatic tumor cell line TD2 bears the characteristic pattern of genetic changes with two independently amplified gene loci. Oncogene 2003;22:6802-6809.
37. Morioka CY, Saito S, Kita K, Watanabe A: Curative resection of orthotopically implanted pancreatic cancer in Syrian golden hamsters. Int J Pancreatol 2000;28:207-213.
38. Lee NC, Bouvet M, Nardin S, Jiang P, Baranov E, Rashidi B, Yang M, Wang X, Moossa AR, Hoffman RM: Anti-metastatic efficacy of adjuvant gemcitabine in a pancreatic cancer orthotopic model. Clin Exp Metastasis 2001;18:379-384.
39. Trauzold A, Wermann H, Arlt A, Schutze S, Schafer H, Oestern S, Roder C, Ungefroren H, Lampe E, Heinrich M, Walczak H, Kalthoff H: CD95 and TRAIL receptor-mediated activation of protein kinase C and NF-κB contributes to apoptosis resistance in ductal pancreatic adenocarcinoma cells. Oncogene 2001;20:4258-4269.